Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306178425> ?p ?o ?g. }
- W4306178425 endingPage "500" @default.
- W4306178425 startingPage "488" @default.
- W4306178425 abstract "Abstract Purpose: Therapy resistance and fatal disease progression in glioblastoma are thought to result from the dynamics of intra-tumor heterogeneity. This study aimed at identifying and molecularly targeting tumor cells that can survive, adapt, and subclonally expand under primary therapy. Experimental Design: To identify candidate markers and to experimentally access dynamics of subclonal progression in glioblastoma, we established a discovery cohort of paired vital cell samples obtained before and after primary therapy. We further used two independent validation cohorts of paired clinical tissues to test our findings. Follow-up preclinical treatment strategies were evaluated in patient-derived xenografts. Results: We describe, in clinical samples, an archetype of rare ALDH1A1+ tumor cells that enrich and acquire AKT-mediated drug resistance in response to standard-of-care temozolomide (TMZ). Importantly, we observe that drug resistance of ALDH1A1+ cells is not intrinsic, but rather an adaptive mechanism emerging exclusively after TMZ treatment. In patient cells and xenograft models of disease, we recapitulate the enrichment of ALDH1A1+ cells under the influence of TMZ. We demonstrate that their subclonal progression is AKT-driven and can be interfered with by well-timed sequential rather than simultaneous antitumor combination strategy. Conclusions: Drug-resistant ALDH1A1+/pAKT+ subclones accumulate in patient tissues upon adaptation to TMZ therapy. These subclones may therefore represent a dynamic target in glioblastoma. Our study proposes the combination of TMZ and AKT inhibitors in a sequential treatment schedule as a rationale for future clinical investigation." @default.
- W4306178425 created "2022-10-14" @default.
- W4306178425 creator A5001167896 @default.
- W4306178425 creator A5013955860 @default.
- W4306178425 creator A5014129073 @default.
- W4306178425 creator A5016044284 @default.
- W4306178425 creator A5016533341 @default.
- W4306178425 creator A5017177249 @default.
- W4306178425 creator A5019557839 @default.
- W4306178425 creator A5025477516 @default.
- W4306178425 creator A5025856946 @default.
- W4306178425 creator A5025880687 @default.
- W4306178425 creator A5026540360 @default.
- W4306178425 creator A5026784314 @default.
- W4306178425 creator A5027219967 @default.
- W4306178425 creator A5031780975 @default.
- W4306178425 creator A5038996741 @default.
- W4306178425 creator A5039918662 @default.
- W4306178425 creator A5044862409 @default.
- W4306178425 creator A5045305178 @default.
- W4306178425 creator A5046496883 @default.
- W4306178425 creator A5046846605 @default.
- W4306178425 creator A5048000779 @default.
- W4306178425 creator A5050699846 @default.
- W4306178425 creator A5050894746 @default.
- W4306178425 creator A5051467826 @default.
- W4306178425 creator A5052523213 @default.
- W4306178425 creator A5054001409 @default.
- W4306178425 creator A5056119087 @default.
- W4306178425 creator A5071888326 @default.
- W4306178425 creator A5081845956 @default.
- W4306178425 creator A5085469014 @default.
- W4306178425 creator A5086321117 @default.
- W4306178425 creator A5087243861 @default.
- W4306178425 creator A5089862646 @default.
- W4306178425 creator A5091333476 @default.
- W4306178425 date "2022-10-14" @default.
- W4306178425 modified "2023-10-16" @default.
- W4306178425 title "A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma" @default.
- W4306178425 cites W1552614585 @default.
- W4306178425 cites W1835812625 @default.
- W4306178425 cites W1984857864 @default.
- W4306178425 cites W1994252736 @default.
- W4306178425 cites W2003059099 @default.
- W4306178425 cites W2007425554 @default.
- W4306178425 cites W2011340259 @default.
- W4306178425 cites W2024672608 @default.
- W4306178425 cites W2029962300 @default.
- W4306178425 cites W2034672909 @default.
- W4306178425 cites W2043029667 @default.
- W4306178425 cites W2044614871 @default.
- W4306178425 cites W2045989148 @default.
- W4306178425 cites W2052346793 @default.
- W4306178425 cites W2060551076 @default.
- W4306178425 cites W2061061337 @default.
- W4306178425 cites W2068422827 @default.
- W4306178425 cites W2078510083 @default.
- W4306178425 cites W2083820705 @default.
- W4306178425 cites W2088439868 @default.
- W4306178425 cites W2104032759 @default.
- W4306178425 cites W2115276344 @default.
- W4306178425 cites W2121396361 @default.
- W4306178425 cites W2129929326 @default.
- W4306178425 cites W2160734881 @default.
- W4306178425 cites W2165244997 @default.
- W4306178425 cites W2325707043 @default.
- W4306178425 cites W2392045628 @default.
- W4306178425 cites W2516432787 @default.
- W4306178425 cites W2518531630 @default.
- W4306178425 cites W2561012755 @default.
- W4306178425 cites W2566753678 @default.
- W4306178425 cites W2613226689 @default.
- W4306178425 cites W2620241325 @default.
- W4306178425 cites W2789281724 @default.
- W4306178425 cites W2918245010 @default.
- W4306178425 cites W2922948425 @default.
- W4306178425 cites W2936671056 @default.
- W4306178425 cites W2947077207 @default.
- W4306178425 cites W2955935498 @default.
- W4306178425 cites W2963868337 @default.
- W4306178425 cites W2980663762 @default.
- W4306178425 cites W2981722946 @default.
- W4306178425 cites W2990647095 @default.
- W4306178425 cites W3016250405 @default.
- W4306178425 cites W3092607059 @default.
- W4306178425 cites W3109004754 @default.
- W4306178425 cites W3110787789 @default.
- W4306178425 cites W3129487631 @default.
- W4306178425 cites W3137849668 @default.
- W4306178425 cites W3154958921 @default.
- W4306178425 cites W3158045410 @default.
- W4306178425 cites W3161800158 @default.
- W4306178425 cites W3174246647 @default.
- W4306178425 cites W4200347391 @default.
- W4306178425 cites W4281809721 @default.
- W4306178425 cites W4282982555 @default.
- W4306178425 cites W4283360415 @default.
- W4306178425 cites W4285093397 @default.